ArticleFrontiers in neurology2025
Exosomal circ_0093708 as a potential ferroptosis biomarker in cerebral ischemia-reperfusion injury.
Article in Frontiers in neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Ferroptosis plays a critical role in neuronal injury following cerebral infarction. However, effective therapeutic strategies targeting ferroptosis after cerebral ischemia-reperfusion injury (CI/RI) remain limited. Exosome-based therapy holds significant promise in this context. This study aims to identify key exosomal markers of ferroptosis. Methods: By integrating and analyzing multiple GSE datasets, we identified ferroptosis-associated key genes. These findings were further validated in external databases, cellular models, and animal experiments using malondialdehyde (MDA), glutathione (GSH), iron, reactive oxygen species (ROS) assays, qRT-PCR, Western blotting. By further establishing a ferroptosis model and inhibiting DUSP1 with drugs, we further explored the potential function of DUSP1 in ferroptosis. The role of miR-101-3p was assessed in CI/RI models, while the diagnostic value of exosomal circular RNA was evaluated using receiver operating characteristic curve analysis. Results: Combined differential analysis revealed PTGS2 and DUSP1 as ferroptosis-associated genes potentially regulated by exosomal circRNAs. In cellular and animal models, ferroptosis post-CI/RI was confirmed by elevated MDA, iron, and ROS levels, alongside reduced GSH. DUSP1 expression was significantly upregulated during ferroptosis, as demonstrated by qRT-PCR, Western blotting, and immunofluorescence. In the simple ferroptosis model, the expression of DUSP1 increases and inhibiting DUSP1 can aggravate ferroptosis. Conversely, miR-101-3p was downregulated in CI/RI, consistent with database predictions. Notably, exosomal circ_0093708 exhibited high diagnostic accuracy (Area under the curve = 0.93, sensitivity = 90%, specificity = 90%). Bioinformatics analysis suggested binding interactions among circ_0093708, miR-101-3p, and DUSP1. Conclusion: Exosomal circ_0093708 is linked to DUSP1 and PTGS2 expression by sponging miR-101-3p, positioning it as a potential biomarker for ferroptosis in CI/RI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.